BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 22655063)

  • 1. Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.
    Sack BK; Merchant S; Markusic DM; Nathwani AC; Davidoff AM; Byrne BJ; Herzog RW
    PLoS One; 2012; 7(5):e37671. PubMed ID: 22655063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B Cell Depletion Eliminates FVIII Memory B Cells and Enhances AAV8-coF8 Immune Tolerance Induction When Combined With Rapamycin.
    Biswas M; Palaschak B; Kumar SRP; Rana J; Markusic DM
    Front Immunol; 2020; 11():1293. PubMed ID: 32670285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of Adeno-Associated Viral Vector-Mediated Human Factor VIII Gene Therapy in Hemophilia A Mice.
    Greig JA; Wang Q; Reicherter AL; Chen SJ; Hanlon AL; Tipper CH; Clark KR; Wadsworth S; Wang L; Wilson JM
    Hum Gene Ther; 2017 May; 28(5):392-402. PubMed ID: 28056565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy for inhibitor reversal in haemophilia A using monoclonal anti-CD20 and rapamycin.
    Biswas M; Rogers GL; Sherman A; Byrne BJ; Markusic DM; Jiang H; Herzog RW
    Thromb Haemost; 2017 Jan; 117(1):33-43. PubMed ID: 27683758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated.
    Chen Y; Luo X; Schroeder JA; Chen J; Baumgartner CK; Hu J; Shi Q
    J Thromb Haemost; 2017 Oct; 15(10):1994-2004. PubMed ID: 28799202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transient blockade of the inducible costimulator pathway generates long-term tolerance to factor VIII after nonviral gene transfer into hemophilia A mice.
    Peng B; Ye P; Blazar BR; Freeman GJ; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2008 Sep; 112(5):1662-72. PubMed ID: 18574023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of B-cell depletion using anti-CD20 therapy on inhibitory antibody formation to human FVIII in hemophilia A mice.
    Zhang AH; Skupsky J; Scott DW
    Blood; 2011 Feb; 117(7):2223-6. PubMed ID: 21160036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A.
    Evans GL; Morgan RA
    Proc Natl Acad Sci U S A; 1998 May; 95(10):5734-9. PubMed ID: 9576953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy.
    Peng B; Ye P; Rawlings DJ; Ochs HD; Miao CH
    Blood; 2009 Nov; 114(20):4373-82. PubMed ID: 19770362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell-activating factor modulates the factor VIII immune response in hemophilia A.
    Doshi BS; Rana J; Castaman G; Shaheen MA; Kaczmarek R; Butterfield JS; Meeks SL; Leissinger C; Biswas M; Arruda VR
    J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33651716
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of the immune response to adenovirus-mediated factor VIII gene therapy in different inbred hemophilic mouse strains.
    Rawle FE; Shi CX; Brown B; McKinven A; Tinlin S; Graham FL; Hough C; Lillicrap D
    J Gene Med; 2004 Dec; 6(12):1358-68. PubMed ID: 15493040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant.
    McIntosh J; Lenting PJ; Rosales C; Lee D; Rabbanian S; Raj D; Patel N; Tuddenham EG; Christophe OD; McVey JH; Waddington S; Nienhuis AW; Gray JT; Fagone P; Mingozzi F; Zhou SZ; High KA; Cancio M; Ng CY; Zhou J; Morton CL; Davidoff AM; Nathwani AC
    Blood; 2013 Apr; 121(17):3335-44. PubMed ID: 23426947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice.
    Miao CH; Ye P; Thompson AR; Rawlings DJ; Ochs HD
    Blood; 2006 Jul; 108(1):19-27. PubMed ID: 16507778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Novel Platform for Immune Tolerance Induction in Hemophilia A Mice.
    Merlin S; Cannizzo ES; Borroni E; Bruscaggin V; Schinco P; Tulalamba W; Chuah MK; Arruda VR; VandenDriessche T; Prat M; Valente G; Follenzi A
    Mol Ther; 2017 Aug; 25(8):1815-1830. PubMed ID: 28552407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic stem cells encoding porcine factor VIII induce pro-coagulant activity in hemophilia A mice with pre-existing factor VIII immunity.
    Doering CB; Gangadharan B; Dukart HZ; Spencer HT
    Mol Ther; 2007 Jun; 15(6):1093-9. PubMed ID: 17387335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors.
    Chuah MK; Schiedner G; Thorrez L; Brown B; Johnston M; Gillijns V; Hertel S; Van Rooijen N; Lillicrap D; Collen D; VandenDriessche T; Kochanek S
    Blood; 2003 Mar; 101(5):1734-43. PubMed ID: 12406898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice.
    Xu L; Mei M; Ma X; Ponder KP
    J Thromb Haemost; 2007 Sep; 5(9):1805-12. PubMed ID: 17596134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.